The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Colorectal Cancer.

Considering the susceptibility and infection rate of transmasculine individuals and cis-gender women are comparable; ...